Guardant Health
VerifiedImproving patient health through technology breakthroughs in oncology..
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$4.0b (Public information from Jul 2024)
Share price
$31.93 GH
Palo Alto California (HQ)
Deals in current and previous year:
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 34 % | 30 % | 20 % | 25 % | 18 % | 21 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (84 %) | (102 %) | (145 %) | (77 %) | (51 %) | (35 %) | (27 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (89 %) | (109 %) | (146 %) | (85 %) | (60 %) | (45 %) | (33 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 52 % | 70 % | 83 % | 65 % | - | - | - |
Source: Dealroom estimates
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor investor | $0.0 | round |
| investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 Valuation: $0.0 32.1x EV/LTM Revenues -21.2x EV/LTM EBITDA | round | |
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
* | $288k | Post IPO Equity | |
| Total Funding | 000k | ||
Related Content
Recent News about Guardant Health
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Guardant Health
Edit
exited